在美国
可用的剂型:
治疗类别:抗生素
药理类别:β-内酰胺
化学类别:碳青霉烯
亚胺培南和西司他丁的组合可用于治疗细菌引起的感染。它通过杀死细菌或阻止其生长而起作用。亚胺培南和西司他丁对感冒,流感或其他病毒感染无效。
亚胺培南和西司他丁的组合可用于治疗身体许多不同部位的感染。有时与其他抗生素一起服用。
亚胺培南和西司他丁只能在医生的处方下使用。
在决定使用药物时,必须权衡服用药物的风险和所能带来的好处。这是您和您的医生会做出的决定。对于亚胺培南和西司他丁,应考虑以下因素:
告诉医生您是否对亚胺培南和西司他丁或任何其他药物有任何异常或过敏反应。如果您还有其他类型的过敏症,例如食物,染料,防腐剂或动物,也请告知您的医疗保健专业人员。对于非处方产品,请仔细阅读标签或包装成分。
亚胺培南和西司他丁已经在有限的12岁及12岁以上儿童中进行了测试,并且尚未报告有效剂量的儿童会引起与成人不同的副作用或问题。
尚未针对老年人专门研究许多药物。因此,可能不知道他们的工作方式是否与年轻人相同。尽管尚无比较老年人使用亚胺培南和西司他丁与其他年龄组的具体信息,但预计亚胺培南和西司他丁在老年人中不会引起与年轻人不同的副作用或问题。
妇女没有足够的研究来确定在母乳喂养期间使用这种药物的婴儿风险。在母乳喂养期间服用这种药物之前,要权衡潜在收益与潜在风险。
尽管某些药物根本不能同时使用,但在其他情况下,即使可能发生相互作用,也可以同时使用两种不同的药物。在这些情况下,您的医生可能希望更改剂量,或者可能需要其他预防措施。当您接受亚胺培南和西司他丁时,您的医疗保健专业人员知道您是否在服用以下列出的任何药物,这一点尤其重要。已根据其潜在重要性选择了以下相互作用,并且不一定是包罗万象的。
通常不建议将亚胺培南和西司他丁与以下任何药物一起使用,但在某些情况下可能需要使用亚胺培南和西司他丁。如果两种药物一起开处方,您的医生可能会更改剂量或使用一种或两种药物的频率。
将亚胺培南和西司他丁与以下任何药物一起使用可能会增加某些副作用的风险,但同时使用这两种药物可能是您的最佳治疗方法。如果两种药物一起开处方,您的医生可能会更改剂量或使用一种或两种药物的频率。
在进食食物或进食某些类型的食物时或前后,不应使用某些药物,因为可能会发生相互作用。在某些药物上使用烟酒也可能引起相互作用。与您的医疗保健专业人员讨论您将药物与食物,酒精或烟草一起使用的情况。
其他医疗问题的存在可能会影响亚胺培南和西司他丁的使用。确保您告诉医生是否还有其他医疗问题,尤其是:
为了完全清除感染,即使几天后您开始感觉好转,也必须在整个治疗期间使用亚胺培南和西司他丁的组合。同样,当血液或尿液中的含量恒定时,亚胺培南和西司他丁的效果最佳。为了使金额保持恒定,必须定期提供。
亚胺培南和西司他丁的剂量因患者而异。遵循医生的命令或标签上的指示。以下信息仅包括亚胺培南和西司他丁的平均剂量。如果您的剂量不同,请不要改变剂量,除非您的医生指示您这样做。
您服用的药物量取决于药物的强度。同样,每天服用的剂量数量,两次给药之间允许的时间以及服用药物的时间长短取决于您正在使用药物的医疗问题。
有些患者在接受亚胺培南和西司他丁时可能会出现震颤或惊厥。如果您已经有癫痫病史,并且正在服用抗惊厥药,那么除非医生另有指示,否则您应该继续服用惊厥药。
在某些患者中,亚胺培南和西司他丁合用可能会引起腹泻。
除了所需的作用外,药物还可能引起某些不良作用。尽管并非所有这些副作用都可能发生,但如果确实发生了,则可能需要医疗护理。
如果出现以下任何副作用,请立即与您的医生联系:
比较普遍;普遍上
不常见
罕见
可能会发生一些通常不需要医疗的副作用。随着身体对药物的适应,这些副作用可能会在治疗期间消失。另外,您的医疗保健专业人员可能会告诉您一些预防或减少这些副作用的方法。请咨询您的医疗保健专业人员,是否持续存在以下不良反应或令人讨厌,或者是否对这些副作用有任何疑问:
比较普遍;普遍上
未列出的其他副作用也可能在某些患者中发生。如果您发现任何其他影响,请咨询您的医疗保健专业人员。
打电话给您的医生,征求有关副作用的医疗建议。您可以通过1-800-FDA-1088向FDA报告副作用。
适用于西司他丁/亚胺培南:溶液粉
西司他丁/亚胺培南及其所需的作用可能会引起一些不良作用。尽管并非所有这些副作用都可能发生,但如果确实发生了,则可能需要医疗护理。
服用西司他丁/亚胺培南时,如果有下列任何副作用,请立即咨询医生:
比较普遍;普遍上
不常见
罕见
西司他丁/亚胺培南可能会产生某些副作用,通常不需要医治。随着身体对药物的适应,这些副作用可能会在治疗期间消失。另外,您的医疗保健专业人员可能会告诉您一些预防或减少这些副作用的方法。
请咨询您的医疗保健专业人员,是否持续存在以下不良反应或令人讨厌,或者是否对这些副作用有任何疑问:
比较普遍;普遍上
适用于西司他丁/亚胺培南:注射剂,肌肉注射剂
常见(1%至10%):注射部位的静脉炎/血栓性静脉炎
罕见(0.1%至1%):注射部位疼痛,注射部位红斑,静脉硬结,局部疼痛和注射部位硬结
未报告频率:灌注静脉感染,注射部位刺激,注射部位反应[参考]
与粒细胞减少症患者相比,粒细胞减少症患者更容易出现与药物相关的恶心和/或呕吐。 [参考]
常见(1%至10%):恶心,呕吐,腹泻
罕见(0.01%至0.1%):伪膜性结肠炎
非常罕见(少于0.01%):出血性结肠炎,胃肠炎,腹痛,舌炎,舌头乳头肥大,烧心,流涎增加
未报告频率:艰难梭菌相关性腹泻,口腔念珠菌病,便秘
上市后报告:牙齿和/或舌头的染色[参考]
常见(1%至10%):皮疹(如发烟性皮疹)
罕见(0.1%至1%):瘙痒,荨麻疹
稀有(0.01%至0.1%):多形性红斑,血管性水肿/血管神经性水肿,剥脱性皮炎
非常罕见(少于0.01%):多汗症,皮肤纹理变化,念珠菌病
上市后报道:史蒂文斯-约翰逊综合征,中毒性表皮坏死
β-内酰胺类:
-未报告频率:严重的皮肤不良反应(包括史蒂文斯-约翰逊综合征,中毒性表皮坏死溶解,嗜酸性粒细胞增多和全身症状的药物反应[DRESS],急性全身性皮疹性脓疱病) [Ref]
常见(1%至10%):嗜酸性粒细胞增多
罕见(0.1%至1%):血小板增多症,库姆斯试验阳性,凝血酶原时间延长,血红蛋白减少
未报告频率:嗜酸性粒细胞增加,白细胞增加,血小板增加,血红蛋白和血细胞比容减少,单核细胞增加,凝血酶原时间异常,淋巴细胞增加,嗜碱性粒细胞增多,嗜中性粒细胞减少,血小板计数增加/减少,血细胞比容增加/减少,贫血
上市后报告:全血细胞减少症,骨髓抑制,中性粒细胞减少症,血小板减少症,白细胞减少症,溶血性贫血,粒细胞缺乏症[参考]
常见(1%至10%):血清转氨酶升高
罕见(0.1%至1%):胆红素升高
未报告的频率:ALT升高,AST升高,胆红素升高/降低
上市后报告:肝炎(包括暴发性肝炎),黄疸,肝衰竭[参考]
常见(1%至10%):碱性磷酸酶增加
罕见(0.1%至1%):发烧
非常罕见(小于0.01%):潮红,乏力/虚弱
未报告频率:LDH增加,血清钠减少,钾增加,氯化物增加,面部浮肿,疼痛,重度感染
上市后报告:药物热[参考]
罕见(0.1%至1%):癫痫发作,肌阵挛性活动,头晕,嗜睡
罕见(0.01%至0.1%):脑病,感觉异常,震颤,听力下降
非常罕见(少于0.01%):重症肌无力,头痛,眩晕,耳鸣加重
未报告频率:肌阵挛
上市后报告:震颤,运动障碍,味觉变态[参考]
罕见(0.1%至1%):低血压
非常罕见(小于0.01%):心pit,心动过速,发[参考]
罕见(0.1%至1%):混乱
上市后报告:精神障碍(包括幻觉),躁动
罕见(0.1%至1%):BUN增加,肌酐增加
稀有(0.01%至0.1%):少尿/无尿
上市后报告:急性肾衰竭[参考]
稀有(0.01%至0.1%):多尿
非常罕见(少于0.01%):外阴瘙痒症
没有报告的频率:尿蛋白的存在,尿红细胞的存在,尿白细胞的存在,尿管的存在,尿胆红素的存在,尿液尿胆原原的存在,尿蛋白的增加,尿细菌的存在
上市后报告:尿液变色[参考]
稀有(0.01%至0.1%):过敏反应
β-内酰胺类:
-频率未报告:超敏(过敏)反应[参考]
非常罕见(少于0.01%):胸部不适,呼吸困难,换气过度,咽痛[参考]
非常罕见(少于0.01%):多关节痛,胸椎痛[参考]
1.“产品信息。Primaxin(亚胺培南)。”宾夕法尼亚州西点市的默克公司。
2. Zhanel GG,Wiebe R,Dilay L等。 “对碳青霉烯的比较研究。”药品67(2007):1027-1052
3. Embil JM,Soto NE,Melnick DA“美洛培南与亚胺培南/西司他丁的事后亚组分析,用于糖尿病患者复杂皮肤和皮肤结构感染的多中心,双盲,随机研究。”临床杂志28(2006):1164-74
4. Rivera M,Crespo M,Teruel JL,Marcen R,Ortuno J“因亚胺培南/西司他丁引起的持续性非卧床腹膜透析患者的神经毒性。” Nephrol表盘移植14(1999):258-9
5. Calandra GB,Brown KR,Grad LC等人,“对亚胺培南/西司他丁治疗的首批2,516例患者的不良经历和耐受性进行了回顾。” Am J Med 78(1985):73-8
6. Chastre J,Wunderink R,Prokocimer P,Lee M,Kaniga K,Friedland I“多利培南与亚胺培南静脉输注对呼吸机相关性肺炎的疗效和安全性:一项多中心,随机研究。” Crit Care Med 36(2008):1089-96
7. Calandra GB,Hesney M,Grad C“对亚胺培南/西司他丁和莫拉西坦的比较疗效,安全性和耐受性的多诊所随机研究。” Eur J临床微生物学3(1984):478-87
8. Lyon JA,“亚胺培南/西司他丁:第一种碳青霉烯类抗生素”。 Drug Intell Clin Pharm 19(1985):894-8
9. Clissold SP,Todd PA,Campoli-Richards DM“亚胺培南/西司他丁:其抗菌活性,药代动力学特性和治疗功效的综述”。毒品33(1987):185-241
10.Patel SA,Braun HL,Fine MS等,“亚胺培南相关的淀粉酶和脂肪酶的升高”。美国胃肠病杂志84(1989):80-1
11. Wang C,Calandra GB,Aziz MA,Brown KR“亚胺培南/西司他丁的疗效和安全性:全球临床经验回顾”。 Rev Infect Dis 7(1985):s528-36
12. Schmitt DV,Leitner E,Welte T,Lode H“ Piperacillin /他唑巴坦与Imipenem / Cilastatin在治疗院内肺炎中的应用-双盲前瞻性多中心研究。”感染34(2006):127-34
13.Young K“亚胺培南/西司他丁”。药物论坛34(1986):1-3
14. Larsen JW,Gabel-Hughes K,Kreter B“亚胺培南-西司他丁与克林霉素+庆大霉素对严重盆腔感染的疗效和耐受性”。临床杂志14(1992):90-6
15. Campise M“亚胺培南/西司他丁治疗尿毒症患者的神经系统并发症”。肾透析透析移植物13(1998):1895-6
16. Roberts JA,Lipman J,“重症监护中的抗菌剂量:败血症的药代动力学,疾病程度和药效动力学”。 Clin Pharmacokinet 45(2006):755-773
17. Oriordan J,Javed M,Doherty C,Hutchinson M“使用亚胺培南/西司他丁治疗重症肌无力”。 J Neurol Neurosurg Psychiatry 57(1994):383。
18. Zazgornik J,Schein W,Heimberger K等人,“在肾脏移植接受者中,亚胺培南与环孢素治疗合用对神经毒性副作用的增强作用:副作用或药物的协同作用。”临床肾病26(1986):265-6
19. Eng RH,Munsif AN,Yangco BG等,“亚胺培南的癫痫发作倾向”。 Arch Intern Med 149(1989):1881-3
20. Lane M,Kania D,Rapp RP“与使用亚胺培南-西司他丁有关的癫痫发作”。美国卫生医学杂志53(1996):1605-6
21. Duque A,Altimiras J,Garcia-Cases C,Vidal P“由静脉注射亚胺培南/西司他丁引起的眩晕”。 DICP 25(1991):1009
22. Semel JD,Allen N“在同时接受茶碱和亚胺培南或环丙沙星或甲硝唑的患者中发作。”南方医学杂志84(1991):465-8
23. Leo RJ,Ballow CH“与亚胺培南使用有关的癫痫发作活动:临床病例报告和文献复习。” DICP 25(1991):351-4
24. Guglielmo BJ,Jacobs RA“剂量监测系统对与亚胺培南-西司他丁相关的癫痫发作频率的影响”。美国卫生医学杂志53(1996):1097-8
25. Frucht S,Eidelberg D“亚胺培南诱发的肌阵挛”。 Mov Disord 12(1997):621-2
26. Job ML,Dretler RH,“使用亚胺培南治疗的癫痫发作:发病率和危险因素。” DICP 24(1990):467-9
27. Guglielmo BJ,Jacobs RA“剂量监测系统对与亚胺培南-西司他丁相关的癫痫发作频率的影响”。美国卫生医学杂志53(1996):2097-8
28. Romano A,中提琴M,Gueant-Rodriguez RM,Gaeta F,Pettinato R,Gueant JL“对青霉素立即过敏的亚胺培南。”英格兰医学杂志354(2006):2835-7
29.令人愉快的RA,Walker TR,Samuelson WM,“对于囊性纤维化患者对肠胃外β-内酰胺类抗生素的过敏反应。”胸部106(1994):1124-8
30. Hantson P,de Coninck B,Horn JL和Mahieu P“对氨曲南和亚胺培南立即过敏。” Br Med J 302(1991):294-5
某些副作用可能没有报道。您可以将其报告给FDA。
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌种类而怀疑/证实感染:每6小时静脉输注1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H菌,克雷伯菌属,粘质沙雷氏菌等易感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌种类而怀疑/证实感染:每6小时静脉输注1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌种类而怀疑/证实感染:每6小时静脉输注1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌种类而怀疑/证实感染:每6小时静脉输注1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌种类而怀疑/证实感染:每6小时静脉输注1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌种类而怀疑/证实感染:每6小时静脉输注1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌物种而怀疑/证实感染:每6小时静脉注射1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而导致的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌物种而怀疑/证实感染:每6小时静脉注射1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌物种而怀疑/证实感染:每6小时静脉注射1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌种类而怀疑/证实感染:每6小时静脉输注1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌种类而怀疑/证实感染:每6小时静脉输注1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌种类而怀疑/证实感染:每6小时静脉输注1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌类(包括脆弱类杆菌)易感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌物种而怀疑/证实感染:每6小时静脉注射1 g(亚胺培南成分)
用途:用于治疗:
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠埃希菌,克雷伯菌,铜绿假单胞菌,沙雷氏菌,拟杆菌等(包括脆弱拟杆菌)的敏感菌株而导致的细菌败血症
-粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),表皮葡萄球菌,肠杆菌,铜绿假单胞菌的易感菌株引起的骨和关节感染
-心内膜炎归因于金黄色葡萄球菌易感菌株(产生青霉素酶的菌株)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,无乳链球菌(B链球菌),肠杆菌属,大肠杆菌,阴道加德纳菌,克雷伯菌,变形杆菌,双歧杆菌属,肽球菌的易感菌株而引起的妇科感染菌属,肽链球菌属,丙酸杆菌属,拟杆菌属(包括脆弱类杆菌)
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的菌株),肠杆菌,柠檬杆菌,肠杆菌,大肠杆菌,克雷伯菌,摩根氏菌,变形杆菌,铜绿假单胞菌,双歧杆菌,梭菌,真细菌属,Peptococcus属,Peptostreptococcus属,Propionibacterium属,Bacteroides属(包括脆弱的B杆菌),Fusobacterium属
-由于金黄色葡萄球菌(产生青霉素酶的分离株),不动杆菌属,肠杆菌属,大肠杆菌,流感嗜血杆菌,副流感H,克雷伯菌,沙雷氏菌的敏感菌株而引起的下呼吸道感染
-由于粪肠球菌,金黄色葡萄球菌(产生青霉素酶的分离株),肠杆菌属,大肠杆菌,克雷伯菌,摩根氏菌,寻常变形杆菌,普罗特里斯氏菌,普罗维登斯氏菌,绿脓杆菌等易感菌株而引起的尿路感染(复杂和不复杂)
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
如果由于中等敏感性细菌物种而怀疑/证实感染:每6小时静脉注射1 g(亚胺培南成分)
用途:用于治疗因粪便大肠杆菌,金黄色葡萄球菌(产生青霉素酶的分离株),表皮葡萄球菌,不动杆菌属,柠檬酸杆菌属,肠杆菌属,大肠杆菌,克雷伯菌属,M morganii,P菌株的易感菌株而引起的皮肤和皮肤结构感染的治疗寻常型,雷氏假单胞菌,铜绿假单胞菌,沙雷氏菌种,肽球菌种,肽链球菌种,拟杆菌属(包括脆弱类杆菌),梭菌属
美国传染病学会(IDSA)建议:
-切口手术部位感染:每6小时静脉注射500 mg
-皮肤,筋膜和肌肉的结节性感染:每6至8小时静脉输注1 g
评论:
-推荐作为单药治疗肠道或泌尿生殖道手术后的切口手术部位感染
-与其他药物一起,推荐作为治疗由于混合感染而引起的皮肤,筋膜和肌肉坏死性感染的首选方案
-有关更多信息,请参考当前指南。
如果怀疑/证实是由于易感染细菌引起的感染:每6小时静脉注射500 mg(亚胺培南组分)或每8小时静脉注射1 g(亚胺培南组分)
If infection suspected/proven due to bacterial species with intermediate susceptibility: 1 g (imipenem component) IV every 6 hours
Use: For the treatment of skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
Infectious Diseases Society of America (IDSA) Recommendations :
-Incisional surgical site infection: 500 mg IV every 6 hours
-Necrotizing infections of the skin, fascia, and muscle: 1 g IV every 6 to 8 hours
评论:
-Recommended as a single-drug regimen for treatment of incisional surgical site infections after intestinal or genitourinary tract surgery
-With other agents, recommended as a preferred regimen for the treatment of necrotizing infections of the skin, fascia, and muscle due to mixed infections
-Current guidelines should be consulted for additional information.
IDSA and American Thoracic Society Recommendations: 500 mg IV every 6 hours
Duration of therapy: 7 days
评论:
-With other agents, recommended as an empiric treatment regimen for clinically suspected ventilator-associated pneumonia in units where such coverage is appropriate
-Recommended as initial empiric therapy for hospital-acquired pneumonia (non-ventilator-associated pneumonia)
-Suspected ventilator-associated pneumonia: Dose may need to be reduced in patients less than 70 kg to prevent seizures.
-Current guidelines should be consulted for additional information.
International Society for Peritoneal Dialysis (ISPD) Recommendations :
Continuous (all exchanges) :
-Loading dose: 250 mg/L intraperitoneally
-Maintenance dose: 50 mg/L intraperitoneally
Intermittent (1 exchange daily): 500 mg intraperitoneally in alternate exchange
评论:
-Recommended for the treatment of peritoneal dialysis (PD)-related peritonitis
-Current guidelines should be consulted for additional information.
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
评论:
-Recommended for non-CNS infections
Uses: For the treatment of :
-Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
-Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
-Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
-Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
-Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
-Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
-Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
-Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations :
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
评论:
-Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
-In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
-Current guidelines should be consulted for additional information.
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
评论:
-Recommended for non-CNS infections
Uses: For the treatment of :
-Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
-Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
-Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
-Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
-Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
-Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
-Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
-Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations :
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
评论:
-Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
-In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
-Current guidelines should be consulted for additional information.
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
评论:
-Recommended for non-CNS infections
Uses: For the treatment of :
-Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
-Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
-Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
-Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
-Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
-Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
-Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
-Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations :
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
评论:
-Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
-In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
-Current guidelines should be consulted for additional information.
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
评论:
-Recommended for non-CNS infections
Uses: For the treatment of :
-Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
-Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
-Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
-Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
-Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
-Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
-Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
-Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations :
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
评论:
-Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
-In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
-Current guidelines should be consulted for additional information.
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
评论:
-Recommended for non-CNS infections
Uses: For the treatment of :
-Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
-Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
-Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
-Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
-Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
-Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
-Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
-Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations :
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
评论:
-Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
-In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
-Current guidelines should be consulted for additional information.
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
评论:
-Recommended for non-CNS infections
Uses: For the treatment of :
-Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
-Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
-Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
-Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
-Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
-Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
-Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
-Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations :
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
评论:
-Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
-In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
-Current guidelines should be consulted for additional information.
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
评论:
-Recommended for non-CNS infections
Uses: For the treatment of :
-Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
-Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
-Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
-Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
-Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
-Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
-Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
-Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations :
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
评论:
-Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
-In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
-Current guidelines should be consulted for additional information.
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
评论:
-Recommended for non-CNS infections
Uses: For the treatment of :
-Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
-Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
-Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
-Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
-Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
-Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
-Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
-Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations :
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
评论:
-Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
-In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
-Current guidelines should be consulted for additional information.
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
评论:
-Recommended for non-CNS infections
Uses: For the treatment of :
-Bacterial septicemia due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, P aeruginosa, Serratia species, Bacteroides species (including B fragilis)
-Bone and joint infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Enterobacter species, P aeruginosa
-Endocarditis due to susceptible strains of S aureus (penicillinase-producing isolates)
-Gynecologic infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, S agalactiae (group B streptococci), Enterobacter species, E coli, G vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis)
-Intraabdominal infections due to susceptible strains of PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, Proteus species, P aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species (including B fragilis), Fusobacterium species
-Lower respiratory tract infections due to susceptible strains of S aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, E coli, H influenzae, H parainfluenzae, Klebsiella species, S marcescens
-Skin and skin structure infections due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), S epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species (including B fragilis), Fusobacterium species
-Urinary tract infections (complicated and uncomplicated) due to susceptible strains of E faecalis, S aureus (penicillinase-producing isolates), Enterobacter species, E coli, Klebsiella species, M morganii, P vulgaris, P rettgeri, P aeruginosa
American Academy of Pediatrics Recommendations :
7 days or younger: 25 mg/kg IV every 12 hours
Greater than 7 days: 25 mg/kg IV every 8 hours
1 month or older: 15 to 25 mg/kg IV 4 times a day
Maximum dose: 4 g/day
评论:
-Caution is recommended when using for treatment of CNS infections due to increased risk of seizures.
-In patients 1 month or older, the higher dose is recommended for P aeruginosa infections.
-Current guidelines should be consulted for additional information.
Less than 1 week, at least 1500 g: 25 mg/kg (imipenem component) IV every 12 hours
1 to 4 weeks, at least 1500 g: 25 mg/kg (imipenem component) IV every 8 hours
4 weeks to 3 months, at least 1500 g: 25 mg/kg (imipenem component) IV every 6 hours
3 months or older: 15 to 25 mg/kg (imipenem component) IV every 6 hours
Maximum dose: 4 g/day
已知总共有34种药物与西司他丁/亚胺培南相互作用。
查看西司他丁/亚胺培南与下列药物的相互作用报告。
西司他丁/亚胺培南与酒精/食物有1种相互作用
西司他丁/亚胺培南有5种疾病相互作用,包括:
具有高度临床意义。避免组合;互动的风险大于收益。 | |
具有中等临床意义。通常避免组合;仅在特殊情况下使用。 | |
临床意义不大。降低风险;评估风险并考虑使用替代药物,采取措施规避相互作用风险和/或制定监测计划。 | |
没有可用的互动信息。 |